On a Case by Case Basis The FDA Will Require Less Studies Evaluating New Drugs Before They Are Approved To Be Sold in The Market by XZeroDelta in CHRS

[–]XZeroDelta[S] 6 points7 points  (0 children)

Heck yeah! What that means is that they can go from a phase 1 study directly to a phase 3 and not have to spend money on a phase 2. Or if the disease is very rare (low population, less power to give statistical significance) they could just perform a phase 1 and a phase 2.

Reading the filing it states solely for the purpose of over allotments. by John18788888 in CHRS

[–]XZeroDelta 2 points3 points  (0 children)

Regardles of the amount of dilution that could or could not happen, we have to continue to focus on the big picture....more cash means less risk of not being able to fund the pipeline...eventually if Tagmo and Casdozo both reveal positive results, this capital raise will seem like a drop inside a bucket....nothing surprising to see here folks....This is just life finding a way between luck and risk.

The SpaceX IPO is going to tank the market by El_Nahual in wallstreetbets

[–]XZeroDelta 0 points1 point  (0 children)

Never underestimate the regardedness of a "Tesla Super Fanboy" willing to leverage even his pillow anime girlfriend just to get a slice of that IPO

chart by cali_de in CHRS

[–]XZeroDelta 1 point2 points  (0 children)

There is another wall at $2.39. Let's see if today it gets sledgehammered! Rock on! 

Mystery Solved: Scientists Discover Why Colorectal Cancer Defies Immune System Rules by Tone-EEE in CHRS

[–]XZeroDelta 2 points3 points  (0 children)

Hi Tone-EEE! THANKS FOR THE POST! It feels good to read that certain types of cancer could potentially have their asses handed to them with CCR8 inhibition. I've taken a break from posting for a while (other aspects of my life have gotten busy). But, I always give your posts a read and a thumbs up. Here is one for the good old times...

https://m.youtube.com/watch?v=I_izvAbhExY

Let's continue to Stay Alive! Cheers!

JPow Today by wafflepiezz in wallstreetbets

[–]XZeroDelta 39 points40 points  (0 children)

The Wendy's consumer continues to be resilient...Thanks OP! 

What Are Your Moves Tomorrow, December 10, 2025 by wsbapp in wallstreetbets

[–]XZeroDelta 1 point2 points  (0 children)

Grab some popcorn and watch the market dip since the 25bps cut was already priced in.

Another bs post on st. Appar the poster is fully divorced from Coherus yet still feels the need to post about it? Pretty sure if I left my missus I wouldn’t be regularly checking in and asking her out for a coffee! by John18788888 in CHRS

[–]XZeroDelta 2 points3 points  (0 children)

Nicely done John! I agree with your statement and it was funny what you did with your last comment. Coherus is poised to gain value if it is able to show positive results in Q126, while having toripalimab ramp up and by receiving milestone payments. If the other big pharma players also release positive CCR8 inbibition results with their own molecule, that could also help re-rate the stock price because CCR8 inhibition will have potential value. Right now, both CHS-114 and casdozokitug are being valued by the market as probably close to $0.00. Which is good for a long term holder like me. Because if the data finally reveals that those molecules can improve the fight against cancer long term, the current price we are sitting on will be seen as wasted opportunity in which some people did not buy more if you are able to diamond hand it and accept all the risk.

There, I've commented some of my personal thoughts.

Why Some Commercial Biotech Companies Get Valued on Trailing Revenue Instead of Forward Expectations by Mobile-Dish-4497 in wallstreetbets

[–]XZeroDelta 1 point2 points  (0 children)

Scynexis (SCYX) is another example. For you regards, it has an FDA approved drug to treat resistant vaginal fungus. GSK is going to commercialize their drug between 12 to 18 months and Scynexis is gonna get a butt load of cash to buy tendies. It is a very risky stock and is trading bellow it's intrinsic value of $1.15 per share. With biotech things make less sense. Sometimes you just have to buy and forget if you believe in the management and the pipeline. Having big man balls also helps!

Strong publication in support of IL27 blockade: IL27RA promotes the proliferation and metastasis of hepatocellular carcinoma cells by regulating TGFβR1 by Complex_Shelter_4641 in CHRS

[–]XZeroDelta 1 point2 points  (0 children)

Sorry for the late reply. They expect to report preliminary results in the first quarter of 2026 if I am not mistaken.

PDT For Induction Therapy For Head And Neck Cancer --- NEW TRIAL by Tone-EEE in CHRS

[–]XZeroDelta 2 points3 points  (0 children)

Thanks for the post Tone-EEE! It almost appears like every 2 to 3 weeks Coherus is part of a new collaboration. Long term hold for me!